Norharmane prevents muscle aging via activation of SKN-1/NRF2 stress response pathways.
Ontology highlight
ABSTRACT: Sarcopenia, the age-related decline in muscle mass and function, is a significant contributor to increased frailty and mortality in the elderly. Currently, no FDA-approved treatment exists for sarcopenia. Here, we identified norharmane (NR), a β-carboline alkaloid, as a potential therapeutic agent for mitigating muscle aging. We aimed to determine the ability of NR to delay muscle aging in Caenorhabditis elegans (C. elegans), mouse, and muscle cells in mice and humans. NR treatment improved swimming ability and increased the maximum velocity in aged C. elegans. Transcriptomic analysis revealed that NR upregulated detoxification genes in C. elegans, including cytochrome P450, UGT, and GST enzymes. NR-induced benefits were dependent on the SKN-1/Nrf2 stress response pathway. In mammalian mod
SUBMITTER: Nirmala FS
PROVIDER: S-EPMC11810848 | biostudies-literature | 2025 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA